ArticleNature communications2019
Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04642326 (Prospective, Parallel, Multicenter Randomized Controlled Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis), which is not on this map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective, Parallel, Multicenter Randomized Controlled Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis
Who cites it
46 citing papers in PubMed, 121 citations in OpenAlex.
- Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.The lancet. Gastroenterology & hepatology · 2020Trial
- Emerging trends and hotspots in lung-protective ventilation from 2006 to 2025: a bibliometric analysis.Journal of thoracic disease · 2026Article
- Comparative evaluation of PEGylated bovine hemoglobin as a perfusate in rat ex vivo lung perfusion.Respiratory research · 2026Article
- Hepatitis B, C, and E viruses in solid organ transplantation: donor and recipient perspectives.JHLT open · 2026Article
- Contributions, bias, and research gaps in large animal ex vivo lung perfusion models: A systematic review.JHLT open · 2025Review
- Ex vivo lung perfusion-to-lung transplant rat survival model with reproducible development of acute lung injury and graft rejection.JHLT open · 2025Article
- An optimized perfusate for enhanced rat ex vivo lung perfusion and lung transplant models.Animal models and experimental medicine · 2025Article
- Scientific advances in the assessment, modification, and generation of transplantable organs for patients with end-stage organ diseases.Lancet (London, England) · 2025Review
- Ex vivo lung perfusion with GLP-1R agonist mitigates ischemia/reperfusion injury through pyroptosis modulation in lung transplantation- an experimental study.International journal of surgery (London, England) · 2025Article
- Cryopreservation of human lung tissue for 3D ex vivo analysis.Respiratory research · 2025Review
- Feasibility and Safety of Ex Vivo Delivery of Rituximab to Lung Allografts in Transplant Recipients at High Risk for Epstein-Barr Virus-associated Posttransplant Lymphoproliferative Disorder.Transplantation direct · 2025Article
- Emerging trends and hotspots in animal experimental research on lung transplantation from 2004 to 2023: a bibliometric analysis.Journal of thoracic disease · 2025Article
- Transplantation, bridging, and support technologies in pulmonary hypertension.The European respiratory journal · 2024Review
- CRISPR-Cas Genome Editing inHuman gene therapy · 2024Article
- Review
- A proof-of-principle for decontamination of transplantation kidney through UV-C exposition of the perfusate solution.Scientific reports · 2024Article
- The Advent of Semi-Elective Lung Transplantation-Prolonged Static Cold Storage at 10°C.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- De Novo Design and Development of a Nutrient-Rich Perfusate for Ex Vivo Lung Perfusion with Cell Culture Models.International journal of molecular sciences · 2023Article
- Ethical implications ofFrontiers in transplantation · 2023Article
- Model of Acute Liver Failure in an Isolated Perfused Porcine Liver-Challenges and Lessons Learned.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Availability of organs is a limiting factor for lung transplantation, leading to substantial mortality rates on the wait list. Use of organs from donors with transmissible viral infections, such as hepatitis C virus (HCV), would increase organ donation, but these organs are generally not offered for transplantation due to a high risk of transmission. Here, we develop a method for treatment of HCV-infected human donor lungs that prevents HCV transmission. Physical viral clearance in combination with germicidal light-based therapies during normothermic ex-vivo Lung Perfusion (EVLP), a method for assessment and treatment of injured donor lungs, inactivates HCV virus in a short period of time. Such treatment is shown to be safe using a large animal EVLP-to-lung transplantation model. This strategy of treating viral infection in a donor organ during preservation could significantly increase the availability of organs for transplantation and encourages further clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.